Sunday , June 25 2017
Home / Medical News

Medical News

Mayo Clinic Research Identifies Potential New Treatment for Breast Cancer Metastasis

ROCHESTER, Minn. — Breast cancer metastasis, the process by which cancer spreads, may be prevented through the new use of a class of drugs already approved by the U.S. Food and Drug Administration. Mayo Clinic researchers have identified that a key drug target, CDK4/6, regulates a cancer metastasis protein, SNAIL, …

Read More »

AACR Project GENIE Releases Large Cancer Genomic Data Set Which Will Aid in Development of Precision Medicine

PHILADELPHIA — The American Association for Cancer Research (AACR) today announced the first public release of cancer genomic data aggregated through its initiative known as AACR Project Genomics Evidence Neoplasia Information Exchange (GENIE). The data set includes nearly 19,000 de-identified genomic records collected from patients who were treated at eight …

Read More »

ACS Research Indicates Cancer Death Rate Has Dropped 25% Since 1991 Peak

January 5, 2017– A steady decline over more than two decades has resulted in a 25% drop in the overall cancer death rate in the United States. The drop equates to 2.1 million fewer cancer deaths between 1991 and 2014. The news comes from Cancer Statistics 2017, the American Cancer …

Read More »

Lycera’s RORgamma Agonist to Begin Phase 1 Trials

NEW YORK and ANN ARBOR, Mich., January 4, 2017 /PRNewswire/ — Lycera Corp., a privately held biopharmaceutical company developing breakthrough immune modulatory medicines, announced today the initiation of a Phase 1/2a clinical trial of the Company’s novel immuno-oncology therapeutic candidate LYC-55716, in patients with advanced, relapsed, or refractory solid tumors. “We …

Read More »

Merrimack Discontinues Phase 2 Trial of MM-302 in HER2-Positive Metastatic Breast Cancer

CAMBRIDGE, Mass., Dec. 21, 2016 /PRNewswire/ — Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that, following a recent independent Data and Safety Monitoring Board (DSMB) recommendation and subsequent futility analysis, it has decided to stop the Phase 2 HERMIONE study of MM-302 (HER2 antibody-targeted liposomal doxorubicin) in HER2-positive metastatic breast cancer …

Read More »

Galapagos Reports Positive Results From Its Phase 2 Study of Its Cystic Fibrosis Drug

Mechelen, Belgium; 20 December 2016 – Galapagos NV (Euronext & NASDAQ: GLPG) reports topline results from its SAPHIRA 1 Phase 2 study in cystic fibrosis patients with potentiator GLPG1837. The SAPHIRA 1 trial included 26 patients with the G551D mutation in CFTR each receiving three sequential doses of GLPG1837. Of …

Read More »

TGA Approves Hospira’s mAb Biosimilar

MELBOURNE, Australia, Aug. 19, 2015 /PRNewswire/ — Hospira today announced that InflectraTM (infliximab), the first monoclonal antibody (mAb) biosimilar therapy, has been registered in Australia.  This registration paves the way for the Federal Government to reduce the cost of some of the most expensive medicines on the Pharmaceutical Benefits Scheme (PBS). …

Read More »

Ten Breakthrough Drugs will Cost the US Nearly $50 Billion Over Ten Years

There has been heavy debate over the high cost of prescription drugs, and an analysis by Avalere Health estimates that the federal government will spend nearly $50 billion over the next decade on ten breakthrough drugs. The US Food and Drug Administration’s (FDA) new Breakthrough Therapy program is designed to …

Read More »

Heron’s Investigational CINV Drug Succeeds in Late-Stage Study

Heron Therapeutics said that its experimental drug for treating chemotherapy-induced nausea and vomiting (CINV) met its primary endpoint in a late-stage study. Following repeated delays, the positive news sent the company’s shares up more than 40 percent in extended trading. Heron announced top-line results from its Phase III MAGIC study, …

Read More »

Genentech’s Investigational Immunotherapy Doubles Survival in Mid-Stage Lung Cancer Trial

Roche’s Genentech recently announced that its investigational immunotherapy doubled the likelihood of survival in lung cancer patients with the highest level of a specific biomarker. Genentech, a member of the Roche Group, announced interim results from its mid-stage study in patients with previously treated non-small cell lung cancer (NSCLC). According …

Read More »